A Phase I Bridging Study to Evaluate the PK, Safety and Tolerability of SR750 in Healthy Subjects
Latest Information Update: 27 Nov 2023
At a glance
- Drugs SR 750 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors SIMR Biotech
- 20 Nov 2023 Status changed from recruiting to completed.
- 01 Mar 2023 Status changed from planning to recruiting.
- 08 Nov 2021 New trial record